Interpace Biosciences®, Inc. Quarterly report pursuant to Section 13 or 15(d)

Quarterly report pursuant to Section 13 or 15(d)

Going Concern (Details Narrative)

Going Concern (Details Narrative) $ in Thousands				1 Months Ended		2 Months Ended	3 Months Ended							9 Months Ended
Going Concern (Details Narrative) $ in Thousands	Oct. 31, 2020	Oct. 19, 2020	Sep. 30, 2020 USD ($)	Jan. 31, 2020 USD ($) shares	Sep. 30, 2019 USD ($)	May 31, 2020 USD ($)	Jun. 30, 2021 USD ($)	Sep. 30, 2020 USD ($)	Jun. 30, 2020 USD ($)	Mar. 31, 2020 USD ($)	Sep. 30, 2019 USD ($)	Jun. 30, 2019 USD ($)	Mar. 31, 2019 USD ($)	Sep. 30, 2020 USD ($) shares	Sep. 30, 2019 USD ($)	Jan. 15, 2021 USD ($)	Jan. 07, 2021 USD ($)	Dec. 31, 2019 USD ($)	Nov. 13, 2018 USD ($)
Cash and cash equivalents			$ 5,308					$ 5,308						$ 5,308				$ 2,321
Accounts receivable, net			8,463					8,463						8,463				10,338
Total current assets			17,632					17,632						17,632				16,510
Total current liabilities			15,601					15,601						15,601				$ 17,292
Net loss								6,234	$ 5,580	$ 6,494	$ 7,446	$ 5,304	$ 3,326	18,308	$ 16,077
Net cash used in operating activities														12,395	$ 12,556
Series B Preferred Stock [Member]
Public offering generating net proceeds				$ 19,200
Sale of common stock \| shares				20,000
Landlord Letter of Credit [Member]
Line of credit facility			1,000					1,000						1,000
SVB Loan Agreement [Member]
Repayment of line of credit														3,400
Line of credit facility			4,000					4,000						$ 4,000
Line of credit facility maturity date														Nov. 13, 2021
Line of credit facility, description														Prior to the termination, the borrowing limit of the Revolver was (a) the lower of: (i) $4.0 million and (ii) 80% of the Company's eligible accounts receivable (as adjusted by SVB), reduced by (b) (i) any outstanding advances under the Revolver, of which there are none as of September 30, 2020; (ii) the Landlord Letter of Credit, in the maximum amount of $1 million; and (iii) any outstanding term loans, of which there was none due to repayment in 2019.
Restricted cash			$ 350					$ 350						$ 350
SVB Loan Agreement [Member] \| Above Prime Rate [Member]
Debt instrument floation interest rate			0.50%
SVB Loan Agreement [Member] \| Maximum [Member]
Maximum adjusted quick ratio			0.0115					0.0115						0.0115
SVB Loan Agreement [Member] \| Minimum [Member]
Maximum adjusted quick ratio			0.010					0.010						0.010
Equity Distribution Agreement [Member]
Public offering generating net proceeds					$ 3,700
ATM Agreement [Member]
Public offering generating net proceeds														$ 700
Sale of common stock \| shares														178,000
Centers for Medicare & Medicaid Services [Member]
Loans payable			$ 2,100					$ 2,100						$ 2,100
Department of Health and Human Services [Member]
Loans payable			650					$ 650						$ 650
Department of Health and Human Services [Member] \| Forecast [Member]
Utilization of advance payment against cash payments							$ 2,100
Asset Purchase Agreement [Member] \| CGI Bio Pharma [Member]
Proceeds from loans payable						$ 888
Silicon Valley Bank [Member]
Repayment of line of credit			$ 3,400
Line of credit facility, description
Silicon Valley Bank [Member] \| SVB Loan Agreement [Member]
Line of credit facility																			$ 4,000
Subsequent Event [Member]
Cash on hand, net of restricted cash																$ 6,100
Subsequent Event [Member] \| Series B Shareholders [Member]
Secured promissory note																	$ 2,000
Subsequent Event [Member] \| Ampersand 2018 Limited Partnership [Member]
Secured promissory note																	$ 3,000
Subsequent Event [Member] \| SVB Loan Agreement [Member]
Debt instrument floation interest rate	4.25%	4.25%
Subsequent Event [Member] \| SVB Loan Agreement [Member] \| Above Prime Rate [Member]
Debt instrument floation interest rate	1.00%	1.00%